Ameriprise
SIOX

Ameriprise’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Ameriprise’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-382,004
Closed -$494K – 4055
2021
Q4 		$494K Buy
382,004
+367,404
+2,516% +$652K ﹤0.01% 3531
2021
Q3 		$32K Hold
14,600
– – ﹤0.01% 3823
2021
Q2 		$40K Buy
+14,600
New +$36.3K ﹤0.01% 3859
2018
Q1 		– Sell
-40,996
Closed -$1.73M – 3719
2017
Q4 		$1.73M Buy
40,996
+16,882
+70% +$757K ﹤0.01% 2725
2017
Q3 		$1.33M Buy
24,114
+20,463
+560% +$3.45M ﹤0.01% 2835
2017
Q2 		$677K Sell
3,651
-3,958
-52% -$694K ﹤0.01% 3110
2017
Q1 		$909K Buy
7,609
+17
+0.2% +$1.78K ﹤0.01% 2939
2016
Q4 		$755K Buy
7,592
+2
+0% +$211 ﹤0.01% 3099
2016
Q3 		$850K Sell
7,590
-63
-0.8% -$7.56K ﹤0.01% 2976
2016
Q2 		$786K Buy
+7,653
New +$765K ﹤0.01% 2987

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Ameriprise's SIOX Position: Q1 2022 in Review

Ameriprise sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 382,004 shares — an estimated $494K sold.

Ameriprise first reported a position in SIOX in Q2 2016 and held it in 10 quarters. The position peaked at $1.73M in Q4 2017. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

  • Ameriprise reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Ameriprise sold 382,004 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $494K.
  • Ameriprise first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2016 and held it in 10 quarters.
  • Ameriprise's Sio Gene Therapies Inc. Common Stock position peaked at $1.73M in Q4 2017.
  • 41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on Ameriprise's 13F filing for Q1 2022, filed 16 May 2022.